May 2013

Although there is still disagreement about what it means, the bundling of payments revolves around oncologists being paid a set fee for managing their patients’ care.

In the wake of the approval of several novel treatments for prostate cancer, physicians must now focus on how best to integrate new therapies into the treatment of patients with prostate cancer.

Working in a laboratory at the National Institutes of Health, Benjamin W. Purow, MD, became the first researcher to demonstrate that the Notch pathway plays a role in gliomas.

Ado-trastuzumab emtansine received FDA approval in February, and a number of ongoing trials now seek to determine whether the antibody-drug conjugate can be combined with other agents.

The American Association for Cancer Research is an annual showcase of the latest scientific cancer research, with updates on phase I, often first-in-human clinical trials.

While there is no standard treatment for most patients with chronic lymphocytic leukemia who are age 65 years and older, several regimens are being tested in clinical trials.

Although biomarkers have been shown to correlate with survival in prostate cancer, the use of biomarkers in the management of these patients may be dependent upon the clinical state and the class of drug evaluated.

In September 2012, the FDA approved regorafenib as a salvage treatment for metastatic colorectal cancer (mCRC) previously treated with chemotherapy, an antivascular endothelial growth factor therapy, or an anti-EGFR therapy.

A new study suggests that even tumor cells with a common genetic background can display functional heterogeneity.

Follicular lymphoma is characterized by repeated treatment responses and then relapses and researchers will need to generate a growing list of drug choices to keep pace with patients’ needs.

In advance of the 2013 American Society of Clinical Oncology annual meeting, Targeted Therapy News spoke with this year’s chair of the Scientific Program Committee, Douglas Yee, MD, about key presentations and sessions that attendees can expect.

Full version of the May 2013 Targeted Therapy News